Clinical trials: Pancreatic Cancer Stage III
Pancreatic Cancer
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without exatecan mesylate in treating pancreatic…
- Trial name
- NCT00023972
- Testing
- exatecan mesylate, gemcitabine hydrochloride
- Where
- 74 sites in United States, Canada and 1 more
- Sponsor
- Daiichi Sankyo
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
- Trial name
- PILLAR (NCT01836432)
- Testing
- FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation
- Where
- 32 sites in United States
- Volunteers
- 302 people
- Sponsor
- NewLink Genetics Corporation
Pancreatic Cancer
Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Electroporation therapy may enhance the ability of chemotherapy drugs to enter tumor cells.
- Trial name
- NCT00027521
- Testing
- bleomycin sulfate, electroporation therapy
- Sponsor
- Ichor Medical Systems Incorporated
Adenocarcinoma
AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer
The purpose of this study is to assess the effect and safety of AXP107-11 alone, and in combination with gemcitabine standard therapy, in patients with advanced or metastatic cancer of the pancreas.
- Trial name
- NCT01182246
- Testing
- AXP107-11
- Where
- 2 sites in Sweden
- Volunteers
- 44 people
- Sponsor
- Axcentua Pharmaceuticals AB
Pancreatic Cancer
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether nitrocamptothecin is more effective than gemcitabine for pancreatic cancer.
- Trial name
- NCT00005869
- Testing
- gemcitabine hydrochloride, rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Pancreatic Cancer
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally…
- Trial name
- NCT07066098
- Testing
- IBI343
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Systemic Treatment-naïve Pancreatic Cancer
HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer
The study is being conducted To evaluate the efficacy of HRS-4642 in combination with gemcitabine plus nab-paclitaxel (AG) (± SHR-1316) versus standard therapy in participants, high-risk resectable/borderline resectable…
- Trial name
- NCT07900789
- Testing
- HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection, Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
- Where
- 2 sites in China
- Volunteers
- 825 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Metastatic Pancreatic Cancer
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
This is a Phase II/III Randomized, Open-Label Clinical Study of GB201 in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy Failure
- Trial name
- NCT03721744
- Testing
- GB201, Paclitaxel, Gemcitabine
- Where
- 38 sites in China, France and 1 more
- Volunteers
- 336 people
- Sponsor
- 1Globe Health Institute LLC
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Pancreas Cancer, Pancreatic Cancer
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Pancreatic Cancer Stage IV, Pancreatic Cancer Stage III
- Trial name
- NCT04137822
- Testing
- IMM-101
- Where
- 2 sites in France, United Kingdom
- Sponsor
- Impatients N.V. trading as myTomorrows
Endocrine Tumors
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
- Trial name
- CLARINET (NCT00353496)
- Testing
- lanreotide (Autogel formulation)
- Where
- 71 sites in United States, Austria and 13 more
- Volunteers
- 264 people
- Sponsor
- Ipsen
Pancreatic Cancer
Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
In patients with unresectable advanced pancreatic cancer, non-inferiority of TS-1 monotherapy and superiority of GEM + TS-1 combination therapy to gemcitabine (GEM) will be verified using survival time.
- Trial name
- GEST (NCT00498225)
- Testing
- Gemcitabine plus TS-1, TS-1, Gemcitabine
- Where
- 12 sites in Japan, Taiwan
- Volunteers
- 834 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Pancreatic Neoplasms
Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer
The purpose of this study is to compare the effectiveness of gemcitabine with or without tipifarnib (R115777) in patients who have advanced pancreatic cancer.
- Trial name
- NCT00005648
- Testing
- Gemcitabine with R115777
- Volunteers
- 688 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pancreatic Cancer
A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic…
- Trial name
- NCT00051467
- Testing
- TNFerade
- Where
- 25 sites in United States
- Sponsor
- GenVec
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive…
- Trial name
- COMPETE (NCT03049189)
- Testing
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 324 people
- Sponsor
- ITM Solucin GmbH
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreatic Cancer
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
- Trial name
- NCT06361888
- Testing
- Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine
- Where
- 52 sites in China
- Volunteers
- 502 people
- Sponsor
- Hutchmed
Pancreatic Cancer
Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00003780
- Testing
- tumor infiltrating lymphocyte therapy, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Meyer Pharmaceuticals
Advanced Neuroendocrine Tumors of Pancreatic Origin
Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced…
- Trial name
- RADIANT-3 (NCT00510068)
- Testing
- Everolimus
- Where
- 82 sites in United States, Belgium and 16 more
- Volunteers
- 410 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499265
- Testing
- gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671
- Where
- 39 sites in Germany, Hungary and 4 more
- Volunteers
- 95 people
- Sponsor
- Heidelberg Pharma AG